Univariate Cox regression analysis of potential prognostic factors for time to metastases and DSS
| Variable . | Time to metastases, hazard ratio (95% CI) . | P . | DSS, hazard ratio (95% CI) . | P . | ||||
|---|---|---|---|---|---|---|---|---|
| Karnofsky performance status | ||||||||
| ≥90% versus <90% | 0.6 (0.1-2.6) | 0.50 | 0.4 (0.1-1.7) | 0.19 | ||||
| Sex | ||||||||
| Female vs. male | 0.9 (0.4-1.9) | 0.82 | 0.7 (0.3-1.8) | 0.49 | ||||
| Largest tumor diameter | ||||||||
| ≤14 mm vs. >14 mm | 2.3 (0.9-5.8) | 0.07 | 3.2 (0.9-11.2) | 0.06 | ||||
| Ciliary body involvement | 1 (0.5-2.2) | 0.96 | 0.6 (0.2-1.8) | 0.40 | ||||
| Extraocular growth | 0.8 (0.2-3.5) | 0.81 | 1.2 (0.3-5.3) | 0.79 | ||||
| PCR* | 6.3 (2.6-15.5) | <0.001 | 10.9 (4-29) | <0.001 | ||||
| Tyrosinase | 6.8 (2.3-20.5) | 0.001 | 8.9 (2.8-28) | <0.001 | ||||
| MelanA/MART1 | 5.2 (1.7-15.4) | 0.003 | 10.3 (3.1-34) | <0.001 | ||||
| Variable . | Time to metastases, hazard ratio (95% CI) . | P . | DSS, hazard ratio (95% CI) . | P . | ||||
|---|---|---|---|---|---|---|---|---|
| Karnofsky performance status | ||||||||
| ≥90% versus <90% | 0.6 (0.1-2.6) | 0.50 | 0.4 (0.1-1.7) | 0.19 | ||||
| Sex | ||||||||
| Female vs. male | 0.9 (0.4-1.9) | 0.82 | 0.7 (0.3-1.8) | 0.49 | ||||
| Largest tumor diameter | ||||||||
| ≤14 mm vs. >14 mm | 2.3 (0.9-5.8) | 0.07 | 3.2 (0.9-11.2) | 0.06 | ||||
| Ciliary body involvement | 1 (0.5-2.2) | 0.96 | 0.6 (0.2-1.8) | 0.40 | ||||
| Extraocular growth | 0.8 (0.2-3.5) | 0.81 | 1.2 (0.3-5.3) | 0.79 | ||||
| PCR* | 6.3 (2.6-15.5) | <0.001 | 10.9 (4-29) | <0.001 | ||||
| Tyrosinase | 6.8 (2.3-20.5) | 0.001 | 8.9 (2.8-28) | <0.001 | ||||
| MelanA/MART1 | 5.2 (1.7-15.4) | 0.003 | 10.3 (3.1-34) | <0.001 | ||||
Abbreviation: 95% CI, 95% confidence interval.
Tyrosinase or MelanA/MART1.